CN114224805A - Hyaluronic acid oral liquid for improving skin elasticity and application - Google Patents
Hyaluronic acid oral liquid for improving skin elasticity and application Download PDFInfo
- Publication number
- CN114224805A CN114224805A CN202210088923.1A CN202210088923A CN114224805A CN 114224805 A CN114224805 A CN 114224805A CN 202210088923 A CN202210088923 A CN 202210088923A CN 114224805 A CN114224805 A CN 114224805A
- Authority
- CN
- China
- Prior art keywords
- extract
- oral liquid
- hyaluronic acid
- content
- sodium hyaluronate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/31—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/68—Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/92—Oral administration
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cosmetics (AREA)
Abstract
The invention discloses hyaluronic acid oral liquid for improving skin elasticity and application. The oral liquid comprises sodium hyaluronate, ceramide, dipotassium glycyrrhizinate, Atractylodis rhizoma extract, beta-carotene, cranberry extract, grapefruit extract, sweetener and water; the molecular weight of the sodium hyaluronate is 10-50 kDa, and the pH value is 6.5-7.0; the content of the sodium hyaluronate is 1.5-2.2%; the content of ceramide is 0.2-0.8%; the content of dipotassium glycyrrhizinate is 0.2-0.8%; the content of the bighead atractylodes rhizome extract is 0.5-1.5%; the content of the cranberry extract is 5-9.5%; the content of the grapefruit extract is 2-6%; the content of beta-carotene is 0.05-0.1%; the content of the sweetening agent is 0.01-0.05%. The oral liquid can effectively increase skin moisture, improve skin elasticity, improve skin luster and reduce fine wrinkles.
Description
Technical Field
The invention relates to hyaluronic acid oral liquid for improving skin elasticity and application.
Background
Hyaluronic acid, also known as hyaluronic acid, is a disaccharide glycosaminoglycan composed of D-glucuronic acid and N-acetylglucosamine and widely distributed in the human and animal bodies. In recent years, hyaluronic acid has been widely used in the field of skin care products to improve the water retention of the skin, to make the skin elastic, and to reduce wrinkles.
After being absorbed by oral administration, the hyaluronic acid has better effect than the local and superficial effects of skin care products, and the effects of the hyaluronic acid are not limited to beautifying and nourishing the face, but also have the effect of caring the skin of the whole body. However, the hyaluronic acid oral liquid in the prior art has limited effects on moisturizing and improving skin elasticity, and therefore, the problem needs to be solved.
Disclosure of Invention
The invention provides a hyaluronic acid oral liquid for improving skin elasticity and application thereof, aiming at solving the problem that the hyaluronic acid oral liquid in the prior art has limited effects on increasing skin moisture and improving skin elasticity.
The inventor unexpectedly finds that if the sodium hyaluronate is only used together with the ceramide, the effective components which can be absorbed by the skin are limited, so that the effects of moisturizing the skin and increasing the skin elasticity are not obvious, and even if the collagen and the antioxidant component are added, the effects are still not ideal. When the sodium hyaluronate, the ceramide, the dipotassium glycyrrhizinate, the bighead atractylodes rhizome extract, the beta-carotene, the cranberry extract and the grapefruit extract are used in a matching manner, the skin moisture and the skin elasticity can be effectively increased, the skin luster can be improved, fine wrinkles can be reduced, and the effect of improving the whole skin can be improved. The preparation process of the sodium hyaluronate is improved, the micromolecular sodium hyaluronate with the molecular weight of 8-20 kDa is obtained, the absorbability of skin on the oral liquid is further improved, and the oral liquid is stable and good in homogeneity.
The invention solves the technical problems through the following technical scheme.
The invention provides hyaluronic acid oral liquid, which comprises sodium hyaluronate, ceramide, dipotassium glycyrrhizinate, an extract of bighead atractylodes rhizome, an extract of cranberry, an extract of grapefruit, beta-carotene, a sweetening agent and water;
the hyaluronic acid oral liquid comprises the following components in percentage by mass:
the content of the sodium hyaluronate is 1.5-2.2%; the content of the ceramide is 0.2-0.8%; the content of the dipotassium glycyrrhizinate is 0.2-0.8%; the content of the bighead atractylodes rhizome extract is 0.5-1.5%; the content of the cranberry extract is 5-9.5%; the content of the grapefruit extract is 2-6%; the content of the beta-carotene is 0.05-0.1%; the content of the sweetening agent is 0.01-0.05%; the sum of the mass percentages of the components is 100 percent;
the preparation method of the hyaluronic acid oral liquid comprises the following steps:
s1, sequentially homogenizing and filtering the mixture of the dipotassium glycyrrhizinate, the white atractylodes rhizome extract, the cranberry extract and the grapefruit extract to obtain an extraction mixture;
s2, sequentially mixing the sodium hyaluronate, the ceramide, the beta-carotene, the sweetener, the water and the extraction mixture, performing membrane filtration and aseptic filling to obtain the product;
the preparation method of the sodium hyaluronate comprises the following steps:
s2.1, dissolving macromolecular sodium hyaluronate in absolute ethyl alcohol, adjusting the pH value to 6.5-7.0, and performing degradation reaction at the temperature of 60-75 ℃ to obtain a first solid product through separation;
s2.2, dissolving the first solid product with water, and adjusting the pH value to 9.5-10.5 for decoloring;
the decolorant for decoloring is hydrogen peroxide, and the temperature for decoloring is 40-50 ℃;
s2.3, adjusting the pH value to 6.5-7.0, adsorbing, and then sequentially filtering and ultrafiltering;
the adsorbent is diatomite; the molecular weight permeability of the ultrafiltration membrane component is 5000-20000;
and S2.4, mixing the sodium hyaluronate solution collected after ultrafiltration with absolute ethyl alcohol, and separating to obtain a second solid product.
In the present invention, the content of the sodium hyaluronate is preferably 1.54%, 1.73%, 1.82%, 2.03% or 2.13%.
In the present invention, the ceramide may be selected from ceramides extracted from rice, konjac, brown rice, wheat or corn.
In the present invention, the dipotassium glycyrrhizinate may be dipotassium glycyrrhizinate which is conventional in the art.
Wherein, the content of the dipotassium glycyrrhizinate is preferably 0.2%, 0.25%, 0.37% or 0.41%.
In the invention, the preparation method of the atractylodes macrocephala koidz extract can comprise the following steps: the preparation method comprises the steps of coarsely crushing the bighead atractylodes rhizome, soaking the bighead atractylodes rhizome in water, heating and refluxing for extraction for 10-24 hours at 50-80 ℃, filtering, concentrating the filtrate, and drying the concentrated solution in vacuum to obtain the bighead atractylodes rhizome extract.
Wherein, the content of the white atractylodes rhizome extract is preferably 0.6%, 0.8%, 1.1%, 1.3% or 1.5%.
In the invention, the preparation method of the cranberry extract can comprise the following steps: soaking the cranberries in a 75% ethanol solution, performing ultrasonic reflux extraction at 40-60 ℃ for 6-15 h, filtering, concentrating the filtrate, and drying the concentrated solution in vacuum to obtain the cranberry extract.
Wherein the cranberry extract is preferably present in an amount of 4.5%, 5%, 7%, 8.5% or 9.5%.
In the present invention, the preparation method of the grapefruit extract may include the steps of: the method comprises the steps of soaking grapefruit peel, grapefruit pulp and grapefruit seeds in a 75% ethanol solution, performing ultrasonic reflux extraction at 40-60 ℃ for 8-20 hours, filtering, concentrating the filtrate, and drying the concentrated solution in vacuum to obtain the cranberry extract.
Wherein, the content of the grapefruit extract is preferably 2%, 2.5%, 3%, 5.5%, or 5.6%.
In the present invention, the beta-carotene may be a beta-carotene that is conventional in the art.
Wherein the content of beta-carotene is preferably 0.05%, 0.07%, 0.09% or 0.1%.
In the present invention, the sweetener may be an edible sweetener conventional in the art, preferably one or more of sorbitol, mannitol and erythritol, preferably sorbitol or mannitol.
Wherein the sweetener is preferably present in an amount of 0.01%, 0.02%, 0.03% or 0.05%.
In a preferred embodiment of the invention, the hyaluronic acid oral liquid consists of 1.73% of sodium hyaluronate, 0.64% of ceramide, 0.41% of dipotassium glycyrrhizinate, 1.5% of bighead atractylodes rhizome extract, 7% of cranberry extract, 3% of grapefruit extract, 0.05% of beta-carotene, 0.05% of sorbitol and 85.62% of water.
In a preferred embodiment of the present invention, the hyaluronic acid oral liquid is composed of 2.03% of sodium hyaluronate, 0.45% of ceramide, 0.37% of dipotassium glycyrrhizinate, 1.3% of rhizoma atractylodis macrocephalae extract, 4.5% of cranberry extract, 5.5% of grapefruit extract, 0.1% of beta-carotene, 0.03% of sorbitol, and 85.72% of water.
In a preferred embodiment of the present invention, the hyaluronic acid oral liquid is composed of 1.54% sodium hyaluronate, 0.8% ceramide, 0.25% dipotassium glycyrrhizinate, 0.8% rhizoma atractylodis macrocephalae extract, 8.5% cranberry extract, 2.5% grapefruit extract, 0.07% beta-carotene, 0.02% sorbitol, and 85.52% water.
In a preferred embodiment of the present invention, the hyaluronic acid oral liquid comprises 2.13% of sodium hyaluronate, 0.45% of ceramide, 0.2% of dipotassium glycyrrhizinate, 1.1% of rhizoma atractylodis macrocephalae extract, 5% of cranberry extract, 5.6% of grapefruit extract, 0.05% of beta-carotene, 0.02% of mannitol, and 85.45% of water.
In a preferred embodiment of the present invention, the hyaluronic acid oral liquid comprises 1.82% of sodium hyaluronate, 0.3% of ceramide, 0.25% of dipotassium glycyrrhizinate, 0.6% of rhizoma atractylodis macrocephalae extract, 9.5% of cranberry extract, 2% of grapefruit extract, 0.09% of beta-carotene, 0.01% of mannitol, and 85.43% of water.
In S1, the number of homogenization is preferably 5 to 15.
In S1, the homogenizing pressure is preferably 100 to 500 bar.
In S2, the mixing temperature is preferably 35 to 45 ℃.
In S2, the mixing is preferably performed by stirring.
In S2, preferably, the membrane of the membrane filtration is a nylon membrane with a pore size of 0.22 μm.
In S2, preferably, the aseptic filling employs a high-voltage pulsed electric field to sterilize the filling bottle, and then the hyaluronic acid oral liquid is filled into the filling bottle and sealed.
Wherein, the sterilization field intensity is preferably 50-60K/cm.
Wherein, the pulse number of the sterilization is preferably 300 to 350.
Wherein, the pulse frequency of the sterilization is preferably 400 to 450 Hz.
Wherein, preferably, the specification of the sterile filling is 15 mL/bottle.
The invention also provides the application of the hyaluronic acid oral liquid in skin protection.
On the basis of the common knowledge in the field, the above preferred conditions can be combined randomly to obtain the preferred embodiments of the invention.
The reagents and starting materials used in the present invention are commercially available.
The positive progress effects of the invention are as follows:
the hyaluronic acid oral liquid disclosed by the invention can effectively increase skin moisture and improve skin elasticity, can improve skin luster, reduces fine wrinkles and has an effect of improving the skin of the whole body. In addition, by improving the preparation process, the micromolecular sodium hyaluronate with the molecular weight of 8-20 kDa is obtained, the absorbability of the skin to the oral liquid is further improved, and the oral liquid is stable and good in homogeneity.
Detailed Description
The invention is further illustrated by the following examples, which are not intended to limit the scope of the invention. The experimental methods without specifying specific conditions in the following examples were selected according to the conventional methods and conditions, or according to the commercial instructions.
In the following examples and comparative examples, the preparation methods of the atractylodes macrocephala koidz extract, cranberry extract and grapefruit extract are as follows, respectively.
The preparation method of the atractylodes macrocephala koidz extract comprises the following steps: pulverizing Atractylodis rhizoma, soaking in water, extracting at 60 deg.C under reflux for 12 hr, filtering, concentrating the filtrate, and vacuum drying to obtain Atractylodis rhizoma extract.
The preparation method of the cranberry extract can comprise the following steps: soaking cranberry in 75% ethanol solution, extracting under reflux at 50 deg.C for 10 hr, filtering, concentrating the filtrate, and vacuum drying to obtain cranberry extract.
The preparation method of the grapefruit extract may comprise the steps of: soaking grapefruit peel, grapefruit pulp and grapefruit seed in 75% ethanol solution, performing ultrasonic reflux extraction at 45 deg.C for 12 hr, filtering, concentrating the filtrate, and vacuum drying to obtain cranberry extract.
Example 1
The mass percentage of each component of the hyaluronic acid oral liquid in example 1 is shown in the following table 1. The hyaluronic acid oral liquid of example 1 was prepared as follows:
(1) under the condition of keeping the room temperature, sequentially homogenizing and filtering mixtures of dipotassium glycyrrhizinate, bighead atractylodes rhizome extract, cranberry extract and grapefruit extract according to the material proportion shown in table 1 to obtain an extraction mixture;
homogenizing at 200 bar;
(2) slowly adding sodium hyaluronate, ceramide, beta-carotene, sweetener and water into the extraction mixture at 35 ℃ according to the proportion shown in the table 1, mixing and uniformly stirring until the sodium hyaluronate, the ceramide, the beta-carotene, the sweetener and the water are completely dissolved;
the preparation method of the sodium hyaluronate comprises the following steps:
s2.1, dissolving macromolecular sodium hyaluronate in absolute ethyl alcohol, adjusting the pH value to 6.8, and carrying out degradation reaction at the temperature of 60 ℃ to obtain a first solid product through separation;
s2.2, dissolving the first solid product by using water, and adjusting the pH value to 10.0 for decoloring;
the decolorant for decoloring is hydrogen peroxide, and the temperature for decoloring is 45 ℃;
s2.3, adjusting the pH value to 6.8, adsorbing, and then sequentially filtering and ultrafiltering;
the adsorbent is diatomite; the molecular weight permeability of the ultrafiltration membrane component is 5000-20000;
s2.4, mixing the sodium hyaluronate solution collected after ultrafiltration with absolute ethyl alcohol, and separating to obtain a second solid product, namely sodium hyaluronate;
(3) performing membrane filtration on the mixture obtained in the step (2) by adopting a nylon membrane with the pore diameter of 0.22 mu m;
(4) cooling the oral liquid after membrane filtration to below room temperature;
(5) and (3) carrying out aseptic filling on the cooled oral liquid, specifically, sterilizing a filling bottle by using a high-voltage pulse electric field (the field intensity is 50K/cm, the pulse number is 350, and the pulse frequency is 450Hz), filling the hyaluronic acid oral liquid into the filling bottle (the volume is 15mL), and sealing.
TABLE 1 Components and amounts (in mass%) of examples 1 to 5 and comparative examples 1 to 3
Examples 2 to 5 and comparative examples 1 to 2
Oral liquids were prepared according to the component formulation shown in table 1, and the operating conditions of the preparation method were the same as in example 1.
The collagen peptide in the comparative example 1 is fish skin collagen peptide, and the molecular weight is 1-3 kDa.
Comparative example 3
Oral liquids were prepared according to the formulation shown in table 1, except for the preparation method of sodium hyaluronate, the operation conditions of the other preparation methods were the same as in example 1.
The method for preparing sodium hyaluronate of comparative example 3 comprises the following steps:
s2.1, dissolving macromolecular sodium hyaluronate in absolute ethyl alcohol, adjusting the pH value to 11.0, performing high-temperature degradation reaction at 120 ℃, cooling, adding 4 times of water for dilution, and performing ultrafiltration;
s2.2, mixing the sodium hyaluronate solution collected after ultrafiltration with absolute ethyl alcohol, and separating to obtain a second solid product, so as to obtain the sodium hyaluronate with the molecular weight range of about 50-100 kDa.
Effect example 1: quality index detection
According to the industrial standard, the hyaluronic acid oral liquid prepared in the examples 1-5 and the comparative examples 1-3 is subjected to quality index detection, and the quality index detection result is shown in table 2.
TABLE 2 quality index test results
As can be seen from Table 2, the oral liquids of examples 1 to 5 and comparative examples 1 to 3 all meet the requirements.
The oral liquids of examples 1-5 have good stability within a shelf life (180 days), and no delamination occurs.
Effect example 2: quality index detection
160 adult female volunteers 25-40 years old were divided into 8 groups, each group had 20 persons, and the hyaluronic acid oral liquids according to examples 1-5 and comparative examples 1-3 were administered to 8 experimental groups, once a day for 45 days.
After completion of the experiment, questionnaires on skin conditions were performed, and the results are shown in table 3.
TABLE 3 comparison table of skin conditions
| Survey item | Example 1 | Example 2 | Example 3 | Example 4 | Example 5 | Comparative example 1 | Comparative example 2 | Comparative example 3 |
| Skin moisturizing | 19 | 20 | 18 | 19 | 16 | 6 | 7 | 12 |
| Elasticity of skin | 18 | 17 | 20 | 17 | 20 | 9 | 7 | 11 |
| Skin lightening | 17 | 17 | 19 | 18 | 19 | 11 | 3 | 14 |
| Reduction of fine lines | 16 | 19 | 18 | 17 | 19 | 4 | 2 | 14 |
| Systemic skin effects | 20 | 20 | 20 | 20 | 20 | 3 | 8 | 11 |
As can be seen from table 3, comparative example 1 did not have the effect of improving skin conditions in the absence of dipotassium glycyrrhizinate, the extract of white atractylodes rhizome, and beta-carotene, although collagen peptides were added. Comparative example 2 in the absence of cranberry extract, grapefruit extract and beta-carotene, vitamin C having an antioxidant effect was not effective in moisturizing, increasing skin elasticity and luster, reducing fine lines, improving the general skin level, and the like, although it was added. The molecular weight of the sodium hyaluronate used in comparative example 3 is larger than that of the sodium hyaluronate used in example 1, and the sodium hyaluronate is not highly absorbable and has a general effect of improving skin conditions.
Claims (10)
1. A hyaluronic acid oral liquid is characterized in that the hyaluronic acid oral liquid comprises sodium hyaluronate, ceramide, dipotassium glycyrrhizinate, white atractylodes rhizome extract, cranberry extract, grapefruit extract, beta-carotene, a sweetening agent and water;
the hyaluronic acid oral liquid comprises the following components in percentage by mass:
the content of the sodium hyaluronate is 1.5-2.2%; the content of the ceramide is 0.2-0.8%; the content of the dipotassium glycyrrhizinate is 0.2-0.8%; the content of the bighead atractylodes rhizome extract is 0.5-1.5%; the content of the cranberry extract is 5-9.5%; the content of the grapefruit extract is 2-6%; the content of the beta-carotene is 0.05-0.1%; the content of the sweetening agent is 0.01-0.05%; the sum of the mass percentages of the components is 100 percent;
the preparation method of the hyaluronic acid oral liquid comprises the following steps:
s1, sequentially homogenizing and filtering the mixture of the dipotassium glycyrrhizinate, the white atractylodes rhizome extract, the cranberry extract and the grapefruit extract to obtain an extraction mixture;
s2, sequentially mixing the sodium hyaluronate, the ceramide, the beta-carotene, the sweetener, the water and the extraction mixture, performing membrane filtration and aseptic filling to obtain the product;
the preparation method of the sodium hyaluronate comprises the following steps:
s2.1, dissolving macromolecular sodium hyaluronate in absolute ethyl alcohol, adjusting the pH value to 6.5-7.0, and performing degradation reaction at the temperature of 60-75 ℃ to obtain a first solid product through separation;
s2.2, dissolving the first solid product with water, and adjusting the pH value to 9.5-10.5 for decoloring;
the decolorant for decoloring is hydrogen peroxide, and the temperature for decoloring is 40-50 ℃;
s2.3, adjusting the pH value to 6.5-7.0, adsorbing, and then sequentially filtering and ultrafiltering;
the adsorbent is diatomite; the molecular weight permeability of the ultrafiltration membrane component is 5000-20000;
and S2.4, mixing the sodium hyaluronate solution collected after ultrafiltration with absolute ethyl alcohol, and separating to obtain a second solid product.
2. The hyaluronic acid oral liquid of claim 1, wherein the sodium hyaluronate is present in an amount of 1.54%, 1.73%, 1.82%, 2.03% or 2.13%;
and/or the ceramide content is 0.3%, 0.45%, 0.64% or 0.8%;
and/or the sweetener is one or more of sorbitol, mannitol and erythritol, preferably sorbitol or mannitol;
and/or the sweetener is present in an amount of 0.01%, 0.02%, 0.03%, or 0.05%.
3. The hyaluronic acid oral liquid of claim 1, wherein the dipotassium glycyrrhizinate is present in an amount of 0.2%, 0.25%, 0.37% or 0.41%;
and/or the content of the atractylodes macrocephala koidz extract is 0.6%, 0.8%, 1.1%, 1.3% or 1.5%;
and/or the cranberry extract content is 4.5%, 5%, 7%, 8.5% or 9.5%;
and/or the grapefruit extract content is 2%, 2.5%, 3%, 5.5%, or 5.6%;
and/or the content of beta-carotene is 0.05%, 0.07%, 0.09% or 0.1%.
4. The hyaluronic acid oral liquid of claim 1, which consists of 1.73% sodium hyaluronate, 0.64% ceramide, 0.41% dipotassium glycyrrhizinate, 1.5% Atractylodis rhizoma extract, 7% cranberry extract, 3% grapefruit extract, 0.05% beta-carotene, 0.05% sorbitol, and 85.62% water;
or the hyaluronic acid oral liquid consists of 2.03% of sodium hyaluronate, 0.45% of ceramide, 0.37% of dipotassium glycyrrhizinate, 1.3% of bighead atractylodes rhizome extract, 4.5% of cranberry extract, 5.5% of grapefruit extract, 0.1% of beta-carotene, 0.03% of sorbitol and 85.72% of water;
or the hyaluronic acid oral liquid consists of 1.54% of sodium hyaluronate, 0.8% of ceramide, 0.25% of dipotassium glycyrrhizinate, 0.8% of bighead atractylodes rhizome extract, 8.5% of cranberry extract, 2.5% of grapefruit extract, 0.07% of beta-carotene, 0.02% of sorbitol and 85.52% of water;
or the hyaluronic acid oral liquid consists of 2.13% of sodium hyaluronate, 0.45% of ceramide, 0.2% of dipotassium glycyrrhizinate, 1.1% of bighead atractylodes rhizome extract, 5% of cranberry extract, 5.6% of grapefruit extract, 0.05% of beta-carotene, 0.02% of mannitol and 85.45% of water;
or the hyaluronic acid oral liquid consists of 1.82% of sodium hyaluronate, 0.3% of ceramide, 0.25% of dipotassium glycyrrhizinate, 0.6% of bighead atractylodes rhizome extract, 9.5% of cranberry extract, 2% of grapefruit extract, 0.09% of beta-carotene, 0.01% of mannitol and 85.43% of water.
5. The hyaluronic acid oral liquid of claim 1, wherein the preparation method of the atractylodes macrocephala koidz extract comprises the following steps: coarsely crushing the bighead atractylodes rhizome, soaking the bighead atractylodes rhizome in water, heating and refluxing for extraction at 50-80 ℃ for 10-24 hours, filtering, concentrating the filtrate, and drying the concentrated solution in vacuum to obtain a bighead atractylodes rhizome extract;
the preparation method of the cranberry extract comprises the following steps: soaking cranberries in a 75% ethanol solution, performing ultrasonic reflux extraction at 40-60 ℃ for 6-15 h, filtering, concentrating the filtrate, and drying the concentrated solution in vacuum to obtain a cranberry extract;
the preparation method of the grapefruit extract comprises the following steps: the method comprises the steps of soaking grapefruit peel, grapefruit pulp and grapefruit seeds in a 75% ethanol solution, performing ultrasonic reflux extraction at 40-60 ℃ for 8-20 hours, filtering, concentrating the filtrate, and drying the concentrated solution in vacuum to obtain the cranberry extract.
6. The hyaluronic acid oral liquid of claim 1, wherein the number of homogenisations in S1 is 5-15;
in S1, the homogenizing pressure is 100-500 bar.
7. The hyaluronic acid oral liquid of claim 1, wherein the mixing temperature in S2 is 35-45 ℃; the mixing mode is stirring;
in S2, the filter membrane for membrane filtration is a nylon membrane with the pore size of 0.22 μm.
8. The hyaluronic acid oral liquid of claim 1, wherein in step S2, the filling bottle is sterilized by high-voltage pulsed electric field, and then the hyaluronic acid oral liquid is filled into the filling bottle and sealed.
9. The hyaluronic acid oral liquid of claim 8, wherein the bactericidal field strength is 50-60K/cm;
and/or the number of the sterilization pulses is 300-350;
and/or the pulse frequency of the sterilization is 400-450 Hz;
and/or the aseptic filling specification is 15 mL/bottle.
10. Use of the hyaluronic acid oral liquid according to any of claims 1-9 for skin protection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210088923.1A CN114224805A (en) | 2022-01-25 | 2022-01-25 | Hyaluronic acid oral liquid for improving skin elasticity and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210088923.1A CN114224805A (en) | 2022-01-25 | 2022-01-25 | Hyaluronic acid oral liquid for improving skin elasticity and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114224805A true CN114224805A (en) | 2022-03-25 |
Family
ID=80747212
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210088923.1A Pending CN114224805A (en) | 2022-01-25 | 2022-01-25 | Hyaluronic acid oral liquid for improving skin elasticity and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114224805A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115918908A (en) * | 2022-12-20 | 2023-04-07 | 济宁医学院附属医院 | Quick-soluble sodium hyaluronate, preparation method, application and product |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101020724A (en) * | 2006-02-14 | 2007-08-22 | 镇江东方生物工程设备技术有限责任公司 | Process of preparing low molecular weight sodium hyaluronate |
| CN106726896A (en) * | 2016-12-06 | 2017-05-31 | 杭州惠博士生物科技有限公司 | A kind of beautifying health composition with anti-inflammatory bacteriostasis efficacy and preparation method thereof |
| CN107156838A (en) * | 2017-05-16 | 2017-09-15 | 宁波君瑞生物科技有限公司 | It is a kind of that there is oral liquid that is anti-oxidant and improving skin condition effect |
| CN112998269A (en) * | 2021-03-19 | 2021-06-22 | 广州能靓生物技术有限公司 | Oral beauty composition and application thereof |
-
2022
- 2022-01-25 CN CN202210088923.1A patent/CN114224805A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101020724A (en) * | 2006-02-14 | 2007-08-22 | 镇江东方生物工程设备技术有限责任公司 | Process of preparing low molecular weight sodium hyaluronate |
| CN106726896A (en) * | 2016-12-06 | 2017-05-31 | 杭州惠博士生物科技有限公司 | A kind of beautifying health composition with anti-inflammatory bacteriostasis efficacy and preparation method thereof |
| CN107156838A (en) * | 2017-05-16 | 2017-09-15 | 宁波君瑞生物科技有限公司 | It is a kind of that there is oral liquid that is anti-oxidant and improving skin condition effect |
| CN112998269A (en) * | 2021-03-19 | 2021-06-22 | 广州能靓生物技术有限公司 | Oral beauty composition and application thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115918908A (en) * | 2022-12-20 | 2023-04-07 | 济宁医学院附属医院 | Quick-soluble sodium hyaluronate, preparation method, application and product |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112998168B (en) | Hyaluronic acid composite polypeptide beverage and preparation method thereof | |
| EP3581192A1 (en) | Composition for enhancing immunity, containing ginseng berry polysaccharides | |
| US20170189464A1 (en) | Method for preparing ginseng polysaccharide for immune stimulation and ginseng polysaccharide for immune stimulation prepared therefrom | |
| CN114224805A (en) | Hyaluronic acid oral liquid for improving skin elasticity and application | |
| KR101883979B1 (en) | pomegranate drink comprising marine collagen and manufacturing method thereof | |
| CN107660671A (en) | A kind of water chestnut skin drinks | |
| JP2015127339A (en) | Composition for anti-saccharification | |
| KR101908695B1 (en) | Method for preparing extracts of Eastern prickly pear and cosmetic compositions and food composition comprising extracts of Eastern prickly pear prepared thereby | |
| CN111939099A (en) | Acne-removing moisturizing mask and preparation method thereof | |
| CN111466576A (en) | Food additive | |
| CN116898098A (en) | Boletus peptide anti-alcoholic formula and raw material preparation method | |
| CN109096392B (en) | Collagen for skin repair and preparation method thereof | |
| CN111328948A (en) | Ginger paste and preparation method thereof | |
| KR102655418B1 (en) | Method For Preparing Collagen Having Low Molecular Weight Derived From Antler | |
| CN108902825A (en) | A kind of preparation method and applications of Chinese yam powder | |
| CN112430516B (en) | Fermented raspberry wine and preparation method thereof | |
| KR102381856B1 (en) | HEALTH FUNCTIONAL FOOD COMPOSITION COMPRISING Hovenia dulcis PEDICEL EXTRACT AS AN EFFECTIVE INGREDIENT AND METHOD FOR VERIFING FUNCTION OF THE SAME | |
| KR102264494B1 (en) | Composition for preventing, improving or treating osteoarthritis using mixture of natural ingredients | |
| CN107212324B (en) | Method for preparing reconstituted pomelo fruit powder from degraded pomelo juice | |
| JP6607418B2 (en) | Anti-glycation composition | |
| KR101905009B1 (en) | Polysaccharide fraction isolated from kale with immune-enhancing activity and method for producing the same | |
| CN105168574A (en) | Healthcare maca oral solution and preparation method thereof | |
| CN110584126A (en) | Functional food with blood sugar reducing effect and preparation method thereof | |
| KR101701809B1 (en) | Red ginseng milk beverage containing black garlic and method for preparing thereof | |
| KR102491278B1 (en) | Food composition including red ginseng and arginine, and a method of preparing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |